Oncology Equipment & Supplies

NRAS mutation is found in several cancers such as melanoma (13~25%), colorectal cancer (1~6%), lung cancer (1%), thyroid cancer (7%) and hepatocellular carcinoma (10%). It is know that the drug response against colorectal cancer medicine such as Erbitux and Cetuximab decreased and the prognosis of the metastatic colorectal cancer patient is bad if the patient has NRAS mutation. Recently, there ...

The Air Sentry HEPA Air Purifier system is a flexible, modular system. It offers Positive Air Pressure solutions for Oncology & Radiology Depts which care for the most immunosuppressed ...

Keller provides medical device and equipment manufacturing for imaging and radio oncology including proton therapy, linac delivered radiotherapy, PET and MRI. We bring expertise in cGMP regulatory environments. Projects include accelerator, cyclotron and magnet-based equipment for imaging or therapeutic ...

Designed for patient comfort during dialysis, oncology, and chemotherapy treatments. For treatments that require substantial chair time, there is no better option for patient comfort than the TRIAD. Developed and adjusted with feedback from patients and healthcare professionals, the TRIAD was designed with all users in ...

AV-353 is the Company’s potent, selective, high affinity inhibitory antibody specific to Notch 3. The Notch 3 signaling pathway is important in cell-to-cell communication involving gene regulation mechanisms that control multiple cell differentiation processes during the entire life cycle. Scientific literature has implicated the Notch 3 receptor pathway in multiple diseases, including ...

UroGen is evaluating UGN-301, our in-licensed anti-CTLA-4 antibody (zalifrelimab), as a monotherapy and as combination therapy with ...

ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers restore ICAM-1 expression which is required for T-cells to leave the circulation and infiltrate the tumor. Activated T cells are then able to infiltrate the tumor and kill ...

Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the immuno-suppressive function of regulatory T cells (Tregs) in tumor microenvironment (TME). Restores T cell function and anti-cancer immune responses in TME. Secures its safety in GLP toxicity ...

Senti Bio believes there are several advantages that NK cells confer in relation to other potential immune cell types in oncology: innate killing, immune activation, previously validated efficacy and safety, and broad patient access since they may be delivered rapidly to patients in an off-the-shelf manner and in outpatient settings. ...

Cancer is the leading cause of death in Japan, with approximately 90% of those deaths said to be caused by solid ...

Built with all the same great features and remarkable efficacy that distinguish the original SRT-100™, the SRT-100 Vision™ delivers the precise, painless calibrated dose of Superficial Radiation Therapy patients and physicians expect, but offers additional features—most notably high-frequency ultrasound for imaging. The SRT-100 Vision™ offers physicians, institutions and ...

Mechanism: ATM inhibitor; Area under investigation: glioblastoma; Date commenced phase: Q2 2018; Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule Status ...

Yondelis® (trabectedin) is a novel marine-derived antitumor agent manufactured by PharmaMar S.A., based in Madrid, Spain. It exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly ...

TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor α (CD123), a target present on a wide range of malignancies including Blastic Plasmacytoid Dendritic Nell Neoplasm (BPDCN). It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP ...

Low profile design – streamlined design helps make dressing simple and efficient and improves patient comfort during long infusion times. Simple safety device activation – clinician-friendly and easy to use; audible click lets you know the needle is locked and enclosed during activation. Non-coring siliconized needle – minimizes irritation while the port is being accessed or ...

F20® radiopaque bone cement is a ready to use, medium viscosity, low exothermic, self-curing bone cement with a high content of radiopaque agent for a perfect level of visualization and safety required during percutaneous vertebral bone augmentation procedures. Its composition has been optimized to get the most suitable handling properties for surgeon’s convenience. F20® comes as an ...

Sensus Healthcare is pleased to introduce Sculptura ™, a groundbreaking state-of-the-art, Directional Anisotropic Radiation Therapy (ART) Platform. Sculptura™ is designed utilizing unique technology and advance features that set it apart from any other platform in the market. The unique design allows you to customize your beam, with fast treatment ...

Mechanism: CDK9 inhibitor Area under investigation: haematalogical malignancies Date commenced phase: Q4 2017 Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule Status change: New to Phase ...

ZetaMet is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone. The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971. Zetagen scientists have discovered an entirely new pathway for this established molecule which, if proven ...

MEN1703 is a dual kinase inhibitor targeting PIM (PIM1, PIM2, PIM 3) and FLT3 kinases. FLT3 internal tandem duplication (FLT3-ITD) is one of the most common genetic lesions in acute myeloid leukemia patients (AML) and is associated with a poor prognosis. PIM kinases are thought to be one of the major drivers of the resistance phenotype to FLT3 inhibitors and their inhibition in relapsed samples ...